Tocilizumab
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB06273 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 100 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | ankylosing spondylitis | KG + DL |
| 2 | rheumatoid vasculitis | KG + DL |
| 3 | hypermobility of coccyx | KG + DL |
| 4 | spondyloarthropathy, susceptibility to | KG + DL |
| 5 | inflammatory spondylopathy | KG + DL |
| 6 | Kummell disease | KG + DL |
| 7 | polyarticular juvenile rheumatoid arthritis | KG + DL |
| 8 | vertebral disease | KG + DL |
| 9 | mendelian susceptibility to mycobacterial diseases due to complete IL12B deficiency | KG + DL |
| 10 | rheumatoid factor-positive polyarticular juvenile idiopathic arthritis | KG + DL |
| 11 | rheumatoid nodulosis | KG + DL |
| 12 | juvenile chronic polyarthritis | KG + DL |
| 13 | autosomal recessive familial Mediterranean fever | KG + DL |
| 14 | anti-glomerular basement membrane disease | KG + DL |
| 15 | WHIM syndrome | KG + DL |
| 16 | systemic mastocytosis | KG + DL |
| 17 | familial Mediterranean fever, autosomal dominant | KG + DL |
| 18 | psoriasis-related juvenile idiopathic arthritis | KG + DL |
| 19 | Smouldering systemic mastocytosis | KG + DL |
| 20 | leukoplakia | KG + DL |
| 21 | lymphoadenopathic mastocytosis with eosinophilia | KG + DL |
| 22 | synovitis (disease) | KG + DL |
| 23 | mantle cell lymphoma | KG + DL |
| 24 | fibroma | KG + DL |
| 25 | gingival hypertrophy | KG + DL |
| 26 | systemic-onset juvenile idiopathic arthritis | KG + DL |
| 27 | discitis | KG + DL |
| 28 | extracutaneous mastocytoma | KG + DL |
| 29 | Czech dysplasia, metatarsal type | KG + DL |
| 30 | spondyloepimetaphyseal dysplasia, Handigodu type | KG + DL |
| 31 | aggressive systemic mastocytosis | KG + DL |
| 32 | platyspondylic dysplasia, Torrance type | KG + DL |
| 33 | infantile systemic hyalinosis | KG + DL |
| 34 | spondylometaphyseal dysplasia, Schmidt type | KG + DL |
| 35 | Quinquaud’s folliculitis decalvans | KG + DL |
| 36 | Waldenstrom macroglobulinemia | KG + DL |
| 37 | avascular necrosis of femoral head, primary | KG + DL |
| 38 | megaepiphyseal dwarfism | KG + DL |
| 39 | hepatic infarction | KG + DL |
| 40 | mild spondyloepiphyseal dysplasia due to COL2A1 mutation with early-onset osteoarthritis | KG + DL |
| 41 | alopecia antibody deficiency | KG + DL |
| 42 | Stickler syndrome, type I, nonsyndromic ocular | KG + DL |
| 43 | achondrogenesis | KG + DL |
| 44 | spondyloperipheral dysplasia-short ulna syndrome | KG + DL |
| 45 | alopecia mucinosa | KG + DL |
| 46 | telogen effluvium | KG + DL |
| 47 | fibrochondrogenesis | KG + DL |
| 48 | Hodgkins lymphoma | KG + DL |
| 49 | Schimke immuno-osseous dysplasia | KG + DL |
| 50 | alopecia areata | KG + DL |
(Showing top 50 of 100 predictions)
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.